Brewer Gregory J, LeRoux Peter D
Departments of Neurology, Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL 62794-9626, USA.
Brain Res. 2007 Jul 9;1157:156-66. doi: 10.1016/j.brainres.2007.04.064. Epub 2007 Apr 30.
Glioblastoma is the most common primary brain tumor in adults from which about 15,000 patients die each year in the United States. Despite aggressive surgery, radiotherapy and chemotherapy, median survival remains only 1 year. Here we evaluate growth of primary human brain tumor cells in a defined nutrient culture medium (Neuregen) that was optimized for neuron regeneration. We hypothesized that Neuregen would inhibit tumor cell growth because of its ability to inhibit gliosis in rat brain. Tumor tissue was collected from 18 patients including 10 males and 8 females (mean age 60+/-12 years) who underwent craniotomy for newly diagnosed, histologically confirmed brain tumors. The tissue was shipped overnight in Hibernate transport medium. Tumor cells were isolated and plated in Neurobasal/serum or Neuregen on culture plastic. After 1 week, growth in Neuregen was significantly less in 9/10 glioblastoma multiforme cases, 5/5 meningioma cases and 3/3 cases of brain metastasis. Analysis of deficient formulations of Neuregen and formulations to which selected components were added back implicate no single active component. However, individual cases were sensitive to corticosterone, selenium, ethanolamine, fatty acids and/or antioxidants. Therefore, a defined culture medium that promotes neuron regeneration inhibits the growth of human primary glioblastoma, meningioma and metastatic tumor cells in culture. The possible in vivo efficacy of Neuregen for treatment of brain tumor resections remains to be determined.
胶质母细胞瘤是成人中最常见的原发性脑肿瘤，在美国每年约有15000名患者死于该病。尽管进行了积极的手术、放疗和化疗，中位生存期仍仅为1年。在此，我们评估了原代人脑肿瘤细胞在一种为神经元再生优化的限定营养培养基（Neuregen）中的生长情况。我们假设Neuregen会抑制肿瘤细胞生长，因为它有能力抑制大鼠脑内的胶质增生。从18例患者身上采集肿瘤组织，其中包括10名男性和8名女性（平均年龄60±12岁），这些患者因新诊断的、组织学确诊的脑肿瘤接受了开颅手术。组织在Hibernate运输培养基中连夜运送。肿瘤细胞被分离出来，接种在培养塑料上的Neurobasal/血清或Neuregen中。1周后，在9/10的多形性胶质母细胞瘤病例、5/5的脑膜瘤病例和3/3的脑转移瘤病例中，Neuregen中的生长明显较少。对Neuregen的缺陷配方以及添加了选定成分的配方进行分析，未发现单一活性成分。然而，个别病例对皮质酮、硒、乙醇胺、脂肪酸和/或抗氧化剂敏感。因此，一种促进神经元再生的限定培养基在培养中可抑制人原发性胶质母细胞瘤、脑膜瘤和转移性肿瘤细胞的生长。Neuregen用于治疗脑肿瘤切除术的体内潜在疗效仍有待确定。
